PA
MYGN icon

PSI Advisors’s Myriad Genetics MYGN Stock Holding History

PSI Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-250
Closed -$7K – 773
2021
Q4 		$7K Hold
250
– – ﹤0.01% 548
2021
Q3 		$8K Buy
+250
New +$8.3K ﹤0.01% 522
2020
Q1 		– Sell
-250
Closed -$6K – 404
2019
Q4 		$6K Buy
+250
New +$6.88K ﹤0.01% 528

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PSI Advisors's MYGN Position: Q1 2022 in Review

PSI Advisors sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 250 shares — an estimated $7K sold.

PSI Advisors first reported a position in MYGN in Q4 2019 and held it in 3 quarters. The position peaked at $8K in Q3 2021. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

  • PSI Advisors reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
  • PSI Advisors sold 250 Myriad Genetics shares in Q1 2022, an estimated $7K.
  • PSI Advisors first reported a position in Myriad Genetics in Q4 2019 and held it in 3 quarters.
  • PSI Advisors's Myriad Genetics position peaked at $8K in Q3 2021.
  • 205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on PSI Advisors's 13F filing for Q1 2022, filed 20 Apr 2022.